Latest News

Research
Monday, April 4, 2016
NAAF representatives traveled to Washington, D.C., this month to attend the largest dermatology event of the year — the 74 th American Academy of Dermatology (AAD) Annual Meeting, which was packed with outstanding educational sessions, poster exhibits, social programs, and endless networking opportunities. Exhilarating new interest in the field of alopecia areata research was evident throughout this five-day meeting, held March 4 to 9, with over 18,500 attendees from across the United States — and the world! NAAF staffers participated in numerous medical and scientific groups that met in...Read more
Advocacy & Awareness
Monday, April 4, 2016
Those who attended last year’s National Alopecia Areata Foundation Annual International Conference in Garden Grove will remember multi-talented Abby Asistio closing the event with an inspirational talk and new song . Recently, Abby had the opportunity to spread awareness of alopecia areata and share her story with none other than Mark Zuckerberg , Founder & CEO of Facebook. Here she describes how this significant meeting came about: “In February 2016, I had an amazing opportunity, not just for me but for the whole alopecia areata community, when I was chosen as 1 of 18 invited by Facebook...Read more
Research
Monday, December 21, 2015
More exciting news for an emerging treatment in alopecia areata, and one patients tend to feel more comfortable with: a topical medication applied directly to the affected areas of hair loss. In the alopecia areata (AA) community, we are more or less familiar with the term “JAK inhibitors” as potential therapy for alopecia areata. Because of their role as immune modulators, having them available as topical agents is a very promising concept, and it has already been tested in mouse models. In this month’s online issue of JAMA Dermatology, Dr. Craiglow and colleagues from Yale University,...Read more
Research
Thursday, December 3, 2015
Another treatment shows success in three patients according to an article just published in the Journal of Allergy and Clinical Immunology . Recent developments in alopecia areata research have pointed out the similarities it shares with other autoimmune diseases. This has been of large benefit, allowing researchers to test medications in alopecia areata that are already approved and proven safe in other conditions. One such medication, ustekinumab, was tested by Dr. Emma Guttman-Yassky, and her research team at Mount Sinai hospital, NYC. Their new publication shows how extensive alopecia...Read more
Research
Monday, November 9, 2015
We are thrilled to announce the publication of NAAF’s fifth Alopecia Areata Research Summit, From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata, in the prestigious Journal of Investigative Dermatology Symposium Proceedings (JIDSP). Our semi-annual research summits serve to distill learning, chart the path forward and guide the research grants made through NAAF’s Treatment Development Program. The 2014 meeting represented a pivotal moment for alopecia areata research and treatment development with early stage clinical trials of drugs targeting...Read more
Advocacy & Awareness
Tuesday, September 22, 2015
For the third consecutive year, 16 Legislative Liaisons selected from 11 states will be joining NAAF’s Communications Director Gary Sherwood and Chief Administration Officer Jeanne Rappoport to meet with the health aides of thirty senators and congressional representatives at their offices in Washington, DC at the end of the month. The Legislative Liaisons will be asking for their lawmakers’ support on advancing alopecia areata research and three critical components of the Alopecia Areata Treatment Development Program: 1. Advance medical research by providing the National Institutes of Health...Read more
Research
Tuesday, September 22, 2015
This year, NAAF received 13 promising Research Grant proposals requesting over $1.8 million in response to our Research Funding Announcements (RFAs) publicized last May. NAAF’s Research Grant opportunities are designed to support scientists and clinicians to pursue promising research ideas and innovative projects that will advance the development or discovery of safe, effective, affordable treatments and a cure for alopecia areata. Each application will undergo a two-step, patient-centered review process to determine its eligibility for funding. The first phase of peer review is currently...Read more
Advocacy & Awareness
Monday, July 20, 2015
The National Alopecia Areata Foundation is raising awareness and increasing understanding of alopecia areata by calling attention to the shared challenges and triumphs of people living with any autoimmune or skin disease, hair loss, or the emotional pain that so often accompanies living with difference. In doing so, we hope to bring our stories to strengthen a budding national dialogue as we work together to increase acceptance and relieve suffering. The SeeUs Campaign is our approach to reducing the stigma of difference and celebrating the uniqueness and resiliency of people living with...Read more
Advocacy & Awareness
Thursday, July 2, 2015
On Thursday, July 2, the Food and Drug Administration (FDA) announced alopecia areata was one of eight diseases selected for a highly-coveted Patient-Focused Drug Development Initiative (PFDDI) meeting during FY 2016- 2017. The FDA committed to PFDDI with the goal of obtaining the patient perspective on certain disease areas. This information is a critical aspect of the FDA’s decision-making as it establishes the context in which the regulatory decision is made, and provides a more systematic approach for obtaining the patients' perspective on disease severity and currently available...Read more
Research
Wednesday, May 27, 2015
NAAF is pleased to publicize the release of 2015 Research Funding Announcements (RFAs) that outline Research Grant opportunities the support scientists and clinicians at various career stages and in numerous aspects of the field to pursue promising research ideas and innovative projects that will advance the development or discovery of safe, effective, affordable treatments and a cure for alopecia areata. These RFAs were publicized at the Society for Investigative Dermatology (SID) conference in Atlanta, Georgia in early May. This was a fitting venue for announcing RFAs since this meeting...Read more
Support & Education
Tuesday, May 12, 2015
We are pleased to announce that NAAF was approved for a Eugene Washington PCORI Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) to support NAAF’s Annual Patient Support Conference this June! The Conference brings together patients, partners, physicians, researchers and industry, providing an ideal forum for patient partner engagement, support and community leadership development. Individuals with alopecia areata and their loved ones gather together to share their experiences with one another and to learn directly from leading scientists and medical professionals...Read more
Research
Friday, April 3, 2015
RXi Pharmaceuticals has entered into a collaboration with Dr. Maria Hordinsky of the University of Minnesota and the National Alopecia Areata Foundation (NAAF) for the study of Samcyprone™ in the treatment of alopecia areata, with the aim to optimize the treatment regimen of diphencyprone is this dermatological disorder, and to better understand the mechanism of action of the drug in this disease. This collaboration could lead to novel targets for development of potent RNAi compounds against this disease based on our sd-rxRNA® platform. Maria K. Hordinsky, M.D. is Professor and Chair of the...Read more
Research
Wednesday, April 1, 2015
On March 22, 2015 a group of seventeen NAAF patient-stakeholders, NAAF staffers Laura Ralph and Maureen Smith, and ten representatives from a biopharmaceutical company convened in New York City, at the request of the biopharma for a focus group to learn more about what patients would want-and not want – in a treatment or cure. The five-hour focus group was filled with personal stories of struggle and triumph, helpful insights about what it means to live with alopecia areata, and important things to consider when developing a treatment such as its safety, efficacy, and durability. All...Read more
Research
Tuesday, March 24, 2015
On March 24, 2015, Genetic Alliance announced the National Alopecia Areata Foundation (NAAF) as one of the fifteen awardees for Phase I of its initiative to create a ‘white label’ of the Platform for Engaging Everyone Responsibly (PEER). PEER enables individuals to share health information with researchers and each other on their own terms to advance an understanding of health and disease, and to accelerate the development of cohorts for clinical trials. The fifteen selected awardees will work with Genetic Alliance to develop and refine the ‘white label’ PEER while engaging their communities...Read more
Support & Education
Wednesday, February 18, 2015
We are pleased to announce Barbara Henderson, an author who writes under the name Bea Davenport, will be hosting her first writing workshops in the United States at NAAF’s 2015 International Conference in Anaheim, California, this June. “There is some evidence to show that creative writing is a therapeutic and personally empowering activity,” Barbara says. “So I hope the workshops will be a fun and entirely suitable addition to the Conference program.” The British author, who teaches creative writing for the Open College of the Arts, the Penguin Random House Writers Academy, and several...Read more

Pages